What is Dicerna?
Founded in 2006 and headquartered in Massachusetts, Dicerna is a biopharmaceutical innovator dedicated to the discovery and development of therapies that leverage ribonucleic acid interference (RNAi). By selectively silencing genes that contribute to disease, the company is at the forefront of precision medicine. Its market position is defined by a robust pipeline and a history of high-profile partnerships, positioning it as a critical player in the global effort to treat rare and chronic conditions through genetic intervention.
How much funding has Dicerna raised?
Dicerna has raised a total of $488.9M across 7 funding rounds:
Series A
$13M
Corporate Investment
$124M
Series B
$29M
Series C
$60M
Stock Offering
$92.9M
Share Placement
$70M
Corporate Investment
$100M
Series A (2008): $13M with participation from Oxford Bioscience Partners, Skyline Ventures, and Abingworth
Corporate Investment (2010): $124M led by Kyowa Hakko Kirin Co.
Series B (2010): $29M supported by Oxford Bioscience Partners, SR One, Abingworth, Skyline Ventures, and Domain Associates
Series C (2013): $60M featuring Omega Funds, Abingworth Management, Brookside Capital, SR One, Oxford Bioscience Partners, RA Capital Advisors, Domain Associates, Skyline Ventures, and Deerfield Management
Stock Issuance/Offering (2014): $92.9M backed by Undisclosed
Share Placement (2017): $70M with participation from Domain Associates, Cormorant Asset Management, RA Capital Advisors, EcoR1 Capital, Skyline Ventures, and Bain Capital
Corporate Investment (2018): $100M led by Eli Lilly & Co.
Key Investors in Dicerna
Oxford Bioscience Partners
Oxford Bioscience Partners is an international venture capital firm specializing in life science technology based investments, with offices in Boston, Massachusetts and Seoul, Korea.
Skyline Ventures
Skyline Ventures is a nationally-known venture capital firm that specializes in investing in outstanding product-focused healthcare companies, with expertise in small molecule and protein therapeutics.
Abingworth
Abingworth is a leading transatlantic life sciences investment firm that helps transform cutting-edge science into novel medicines by providing capital and expertise to top-tier management teams.
What's next for Dicerna?
With the support of its latest strategic investment, Dicerna is well-positioned to accelerate its clinical development programs and expand its therapeutic reach. The company's focus remains on scaling its RNAi platform to address unmet medical needs, leveraging its deep expertise in molecular discovery. As it moves into its next phase of growth, the firm is expected to prioritize the advancement of its lead candidates through late-stage clinical trials, further solidifying its competitive advantage in the biopharmaceutical landscape.
See full Dicerna company page
